智通财经7月23日电，医药巨头赛默飞世尔大涨超10%，公司Q2营收108.5亿美元，超市场预期。 ...

Financial Data and Key Metrics Changes - Revenue for Q2 grew 3% to $10.85 billion, with adjusted operating income increasing 1% to $2.38 billion [6][28] - Adjusted operating margin was 21.9%, and adjusted EPS was $5.36 per share, exceeding guidance [7][26] - Free cash flow was $1.5 billion after $645 million in net capital expenditures, with cash and short-term investments totaling $6.4 billion [30][31] Performance by Business Segment - Life Science Solutions reported a 6% increase in revenue, with organic growth of 4%, driven by bioproduction [32] - Analytical Instruments saw a 3% decline in reported revenue, with organic growth down 4%, primarily due to tariffs and muted demand [34] - Specialty Diagnostics revenue grew 2% year-over-year, with adjusted operating margin at 27% [35] - Laboratory Products and Biopharma Services segment reported a 4% increase in revenue, with organic growth of 3% [36] Market Data and Key Metrics Changes - North America and Europe experienced low single-digit growth, while Asia Pacific declined low single digits, with China seeing a high single-digit decline [27] - The academic and government market faced mid-single-digit revenue decline due to customer hesitancy [9] Company Strategy and Industry Competition - The company focuses on high-impact innovation, trusted partner status, and a strong commercial engine to drive growth [10][12] - Recent product launches include advanced mass spectrometers and a cryo transmission electron microscope, enhancing competitive positioning [11] - The company is actively managing costs and navigating tariff impacts through its PPI business system [18][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth drivers, expecting organic revenue growth of 3% to 6% in 2026 and 2027 [21][23] - The company anticipates a gradual improvement in end markets, particularly in pharma and biotech, with a focus on customer collaboration [20][22] - Management highlighted the importance of maintaining strong relationships with customers to navigate current challenges [12][71] Other Important Information - The CFO announced plans to retire in March 2026, with a transition to the current VP of Financial Operations [46][48] - The company is on track to close the acquisition of Silventum's purification and filtration business by year-end [16][19] Q&A Session Summary Question: What is the long-term growth outlook? - Management expects a long-term organic revenue growth of 7% plus, driven by strong industry fundamentals and share gains [54][59] Question: How will margin expansion be achieved? - Margin expansion of 50 to 70 basis points is expected, leveraging existing tools and PPI capabilities [60][63] Question: How is the biopharma sector responding to macro factors? - The biopharma sector shows broad strength, with strong growth in bioproduction and pharma services despite macro challenges [67][70] Question: What is the outlook for the Analytical Instruments business? - The Analytical Instruments segment is impacted by muted conditions in academic and government sectors, but new product launches are expected to drive share gains [73][81] Question: How is the company managing customer purchasing decisions amid reshoring? - There is heightened interest in expanding US manufacturing capacity, and customers are not pausing purchases in bioproduction [78][80] Question: What is the funding outlook for academic and government sectors? - There is bipartisan support for funding in life sciences, and budgets are expected to stabilize, moving from a headwind to growth [89][94]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 grew 3% to $10.85 billion, with adjusted operating income increasing 1% to $2.38 billion [7][28] - Adjusted operating margin was 21.9%, and adjusted EPS was $5.36 per share, exceeding guidance [7][19] - Year-to-date cash flow from operations was $2.1 billion, with free cash flow at $1.5 billion after net capital expenditures of $645 million [31] Performance by Business Segment - **Life Science Solutions**: Revenue increased 6% year-over-year, with organic growth at 4%. Adjusted operating income rose 6%, and adjusted operating margin was 36.8% [33] - **Analytical Instruments**: Revenue declined 3%, with organic growth down 4%. Adjusted operating income decreased 26%, and adjusted operating margin was 18.8% [34][35] - **Specialty Diagnostics**: Revenue grew 2% year-over-year, with organic revenue flat. Adjusted operating income increased 3%, and adjusted operating margin was 27% [36] - **Laboratory Products and Biopharma Services**: Revenue increased 4%, with organic growth at 3%. Adjusted operating income rose 11%, and adjusted operating margin was 13.8% [37] Market Data and Key Metrics Changes - In the pharma and biotech sector, mid-single-digit growth was achieved, driven by bioproduction and pharma services [8] - Academic and government revenue declined mid-single digits due to customer hesitancy [9] - Diagnostics and Healthcare revenue declined in the low single digits, impacted by challenges in China [10][28] Company Strategy and Industry Competition - The company focuses on three strategic pillars: high-impact innovation, trusted partner status, and a strong commercial engine [11] - Recent product launches include advanced mass spectrometers and a cryo transmission electron microscope, enhancing the company's competitive position [12][13] - The company is actively managing costs and leveraging its PPI business system to navigate tariff impacts and improve operational efficiency [18][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth drivers of the industry, expecting a gradual improvement in end markets [20][23] - The company anticipates organic revenue growth of 3% to 6% in 2026 and 2027, with a long-term outlook of over 7% [21][24] - Management highlighted strong customer relationships and ongoing investments in innovation as key factors for future success [14][23] Other Important Information - The company announced the retirement of CFO Stephen Williamson, with Jim Meyer set to take over in March 2026 [48][50] - The acquisition of Silventum's purification and filtration business is on track to close by year-end [16] Q&A Session Summary Question: Long-term growth outlook and market share - Management provided clarity on the 7% long-term growth outlook, emphasizing strong conviction in industry drivers and share gains [55][60] Question: Margin expansion drivers - Margin expansion is expected to be driven by PPI business system tools and operational efficiencies, despite tariff impacts [62][66] Question: Biopharma investment trends - Management noted broad strength in biopharma, with strong growth in bioproduction and pharma services, indicating a positive outlook [70][72] Question: Analytical Instruments growth outlook - The segment is expected to face challenges due to muted conditions in academic and government sectors, but new product innovations are anticipated to drive share gains [76][86] Question: Reshoring impact - There is increased interest in expanding US manufacturing capacity, with no signs of customers pausing purchases in bioproduction [81][84] Question: Academic and government funding outlook - Bipartisan support for life sciences funding remains strong, with expectations for stabilization in academic and government budgets [98]

Company Performance - Thermo Fisher Scientific reported quarterly earnings of $5.36 per share, exceeding the Zacks Consensus Estimate of $5.22 per share, but slightly down from $5.37 per share a year ago [1] - The earnings surprise for the quarter was +2.68%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - The company posted revenues of $10.86 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.94% and up from $10.54 billion year-over-year [3] Stock Performance - Thermo Fisher shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.3% [4] - The current Zacks Rank for Thermo Fisher is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $5.53 on revenues of $10.87 billion, and for the current fiscal year, it is $22.34 on revenues of $43.7 billion [8] - The outlook for the Medical - Instruments industry, to which Thermo Fisher belongs, is currently in the bottom 33% of over 250 Zacks industries, which may impact the stock's performance [9]

Exhibit 99.1 News Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 Investor Contact Information: Rafael Tejada Thermo Fisher Scientific E-mail: sandy.pound@thermofisher.com E-mail: rafael.tejada@thermofisher.com Thermo Fisher Scientific Reports Second Quarter 2025 Results WALTHAM, Mass. (July 23, 2025) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June ...

Group 1 - Solventum Corporation (SOLV) successfully sold its purification and filtration business to Thermo Fisher Scientific Inc. (TMO) for $4.1 billion [1] - The transaction is viewed as a significant achievement for Solventum Corporation, indicating strong corporate performance and strategic capital allocation [1] - The investing group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as IPOs, mergers & acquisitions, and earnings reports [1]

Company Overview - Thermo Fisher Scientific Inc. is analyzed comprehensively, covering its history, product offerings, technologies, major applications, and end-user industries [1][2] - The report includes details on the company's ownership structure and key management [2] Business Segments - The report outlines the business segments of Thermo Fisher Scientific and provides a detailed list of products offered [8] - It also discusses the applications and end-user industries served by the company [8] Financial Performance - Financial performance is evaluated over the last three years, including key financial highlights and parameters [8] - The financial outlook for the company is provided for the three most recent fiscal years [8] Strategic Analysis - Recent developments such as mergers, acquisitions, partnerships, collaborations, product launches, and innovation initiatives are highlighted [2][9] - An analysis of R&D expenditure from 2023 to 2025 is included, focusing on key areas and technological breakthroughs [3] SWOT Analysis - A detailed SWOT analysis evaluates the micro and macro environment affecting the company's growth trajectory [3][11] - The analysis covers strengths, weaknesses, opportunities, and threats impacting the company's performance [11] Corporate Social Responsibility (ESG) - The report includes an overview of sustainability trends and ESG developments, along with the company's targets [8][11]

Core Insights - The report reveals the operational status and future dynamics of the global and Chinese High-Performance Liquid Chromatography (HPLC) market from 2025 to 2031, highlighting the profound impact of U.S. tariff policies on the HPLC industry and its development trends in the coming years [1] Industry Analysis - The report defines HPLC products and analyzes the core aspects of U.S. tariff policies, indicating that adjustments in these policies affect global supply chains and compel Chinese HPLC companies to accelerate their internationalization to address domestic market saturation and global opportunities [1] - The report predicts the global HPLC industry's scale trends over the next few years, considering optimistic, conservative, and pessimistic scenarios, and assesses the direct impacts of tariff policies on Chinese HPLC companies, including rising costs, increased market entry pressures, and supply chain restructuring challenges [1] Market Share and Competition - The report analyzes the market share of major companies in the global HPLC market, providing revenue, sales, and price data for the past three years, indicating a high market concentration where a few leading companies hold a significant portion of the market [3] - It lists the specifications, parameters, and application fields of HPLC products from major global manufacturers and evaluates the competitive landscape of the industry [3] Strategic Recommendations - The report offers several strategic recommendations for companies, including shifting from export dependence to global capacity layout, optimizing supply chain resilience, diversifying markets, innovating products and building technological barriers, compliance risk management, tariff avoidance strategies, and channel transformation and business model innovation [4] - It forecasts the future landscape of the global HPLC industry, particularly China's role in the global market, emphasizing that the HPLC market will be influenced by technological innovation, policy environment, and market demand [4] Capacity and Market Trends - The report predicts the supply and demand status and future trends of the global HPLC market, indicating steady growth in global HPLC capacity over the next few years, with major regions' market sizes expected to continue expanding [4] - It analyzes the growth potential of traditional and emerging markets, focusing on regions such as ASEAN, Russia, Eastern Europe, Mexico, Brazil, the Middle East, and North Africa [4] Product Types and Applications - The report provides a segmented analysis of the HPLC market by product types such as UVS, FD, RID, ED, and CD, noting their varying market performances, and covers application areas including pharmacies, biotechnology, CROs, academia, and chemical products [4] - It predicts future development trends for each product type and application, supported by detailed data [4] Major Manufacturers - The report lists key manufacturers in the HPLC market, including Agilent, Waters, Shimadzu, Thermo Fisher, PerkinElmer, Hitachi, Jasco, Knauer, Bekman, YoungLin, GBC, and Gilson, detailing their product specifications, market performance, and latest developments [5]

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.22 per share, reflecting a 2.8% decline year over year, with revenues expected to reach $10.65 billion, a 1% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion, a decrease of 0.2% year over year [5]. - 'Revenues- Specialty Diagnostics' are projected to reach $1.14 billion, indicating a 2.5% increase year over year [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.40 billion, reflecting a 2.1% increase year over year [5]. - 'Revenues- Analytical Instruments' are estimated at $1.79 billion, showing a 0.7% increase year over year [6]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.56 billion, a 0.5% increase from the prior year [6]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.98 billion, reflecting a 0.4% increase year over year [7]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $391.38 million, indicating a 3.3% increase year over year [7]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.69 billion, suggesting a 0.9% increase year over year [8]. Stock Performance - Over the past month, shares of Thermo Fisher have returned +8.3%, outperforming the Zacks S&P 500 composite's +5.4% change [8]. - Currently, TMO holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

Core Insights - Thermo Fisher Scientific Inc. (TMO) is expected to report second-quarter 2025 results on July 23, with revenue estimates at $10.65 billion and earnings per share (EPS) at $5.22, indicating a slight revenue increase but a decline in earnings compared to the previous year [1][8] Revenue and Earnings Estimates - The Zacks Consensus Estimate for TMO's revenues is $10.65 billion, reflecting a 1% increase from the prior-year quarter [1] - The consensus estimate for earnings is $5.22 per share, indicating a 2.8% decline from the year-ago quarter [1][8] - Estimates for second-quarter earnings have remained unchanged at $5.22 per share over the past 60 days [2] Segment Performance - The Analytical Instruments segment is projected to generate $1.84 billion in revenues, suggesting a 3.3% year-over-year growth, driven by new AI-enabled platforms [6][8] - The Life-Science Solutions segment is expected to report $2.37 billion in revenues, indicating a 0.5% growth year over year, supported by proteomics and cell therapy initiatives [9][8] - The Specialty Diagnostics segment is anticipated to achieve $1.15 billion in revenues, reflecting a 2.9% growth year over year [11] - The Laboratory Products and Services segment is expected to see revenues of $5.71 billion, suggesting a decline of 0.7% year over year [13] Product Launches and Innovations - TMO launched several cutting-edge technologies, including the Krios 5 Cryo-TEM and the Invitrogen Attune Xenith Flow Cytometer, which are expected to contribute positively to second-quarter revenues [3][4] - The company also introduced the Vulcan Automated Lab and the Transcend ultra-high performance liquid chromatography platform, enhancing efficiency in various applications [5][4] Market Position and Outlook - TMO's strong performance in the Analytical Instruments and Life-Science Solutions segments is expected to bolster its overall revenue despite challenges in the Laboratory Products and Services segment [8][10] - The company has a Zacks Rank of 4, indicating a less favorable outlook for an earnings beat this reporting cycle, with an Earnings ESP of -0.35% [14]